Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 49.22 EUR 0.49% Market Closed
Market Cap: 10.3B EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
0%
Revenue
Forecast
+9%
Operating Income
Forecast
+23%
Net Income
Forecast
+29%

Wall Street
Price Targets

REC Price Targets Summary
Recordati Industria Chimica e Farmaceutica SpA

Wall Street analysts forecast REC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REC is 58.18 EUR with a low forecast of 50.5 EUR and a high forecast of 70.35 EUR.

REC Lowest Forecast
Wall Street Target
50.5 EUR
3% Upside
REC Average Forecast
Wall Street Target
58.18 EUR
18% Upside
REC Highest Forecast
Wall Street Target
70.35 EUR
43% Upside
Lowest
Price Target
50.5 EUR
3% Upside
Average
Price Target
58.18 EUR
18% Upside
Highest
Price Target
70.35 EUR
43% Upside
Recordati Industria Chimica e Farmaceutica SpA Competitors:
Price Targets
A
APPH
Apontis Pharma AG
28% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
16% Upside
CRON
Cronos Group Inc
44% Upside
PBH
Prestige Consumer Healthcare Inc
14% Upside
A
APPH
Apontis Pharma AG
28% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
16% Upside
CRON
Cronos Group Inc
44% Upside
PBH
Prestige Consumer Healthcare Inc
14% Upside
ALM
Almirall SA
34% Upside

Revenue
Forecast

Revenue Estimate
Recordati Industria Chimica e Farmaceutica SpA

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's revenue is 9%. The projected CAGR for the next 3 years is 8%.

9%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Recordati Industria Chimica e Farmaceutica SpA

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's operating income is 9%. The projected CAGR for the next 3 years is 12%.

9%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Recordati Industria Chimica e Farmaceutica SpA

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's net income is 7%. The projected CAGR for the next 3 years is 19%.

7%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
REC intrinsic value, competitors valuation, and company profile.
DCF Valuation
REC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REC stock valuation using valuation multiples.
Wall Street Estimates
REC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is REC's stock price target?
Price Target
58.18 EUR

According to Wall Street analysts, the average 1-year price target for REC is 58.18 EUR with a low forecast of 50.5 EUR and a high forecast of 70.35 EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's revenue is 9%. The projected CAGR for the next 3 years is 8%.

What is Recordati Industria Chimica e Farmaceutica SpA's Operating Income forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's operating income is 9%. The projected CAGR for the next 3 years is 12%.

What is Recordati Industria Chimica e Farmaceutica SpA's Net Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Recordati Industria Chimica e Farmaceutica SpA's net income is 7%. The projected CAGR for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.